A systematic review and meta-analysis of immunohistochemical biomarkers that differentiate chromophobe renal cell carcinoma from renal oncocytoma

Ng KL 1 , Morais C 2 , Bernard A 3 , Saunders N 4 , Samaratunga H 5 , Gobe G 2 Show all authors , Wood S 6

Affiliations 

  • 1 Department of Urology, Princess Alexandra Hospital, Brisbane, Australia Centre for Kidney Disease Research, School of Medicine, Translational Research Institute, University of Queensland, Brisbane, Australia Department of Surgery, University Malaya, Kuala Lumpur, Malaysia
  • 2 Centre for Kidney Disease Research, School of Medicine, Translational Research Institute, University of Queensland, Brisbane, Australia
  • 3 QFAB Bioinformatics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
  • 4 University of Queensland Diamantina Institute, University of Queensland, Brisbane, Australia
  • 5 Aquesta Pathology, Brisbane, Australia
  • 6 Department of Urology, Princess Alexandra Hospital, Brisbane, Australia
J Clin Pathol, 2016 Aug;69(8):661-71.
PMID: 26951082 DOI: 10.1136/jclinpath-2015-203585

Abstract

Numerous immunohistochemical (IHC) biomarkers have been employed to aid in the difficult differentiation between chromophobe renal cell carcinoma (chRCC) and renal oncocytoma (RO). A systematic review and meta-analysis of the published literature was carried out to summarise and analyse the evidence for discriminatory IHC biomarkers to differentiate the two entities.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications